Pharmacological treatment of the maintenance phase of bipolar depression: focus on relapse prevention studies and the impact of design on generalizability
The goal of pharmacological treatment of bipolar disorder is to prevent future occurrences of mood episodes. To achieve this goal, medications must demonstrate efficacy in the prevention of both manic/hypomanic and depressive relapses/recurrences. Currently, the efficacy of most pharmacological agents in the maintenance treatment of bipolar disorder has been studied using relapse prevention designs, in which only patients who tolerate and respond to a studied drug(s) in the acute phase (mania or depression) can enter the maintenance phase. Subsequently, the results from relapse prevention studies are not generalizable, not only because of the design, but also because of different index mood episodes. So far, however, only lithium and lamotrigine, and to some extent divalproex, have been investigated in both manic and depressive index episodes, while olanzapine and aripiprazole have been evaluated in manic index episodes. To facilitate the application of currently available data, this chapter will systematically examine randomized, blinded, controlled maintenance studies enrolling ≥100 patients and lasting ≥6 months.
KeywordsBipolar Disorder Maintenance Phase Relapse Prevention Bipolar Depression Young Mania Rate Scale
Unable to display preview. Download preview PDF.
- 6.Goodwin F, Jamison K (eds): (2007) Manic-depressive illness: bipolar disorder and recurrent depression, 2nd edition. Oxford University Press, New YorkGoogle Scholar
- 13.Prien RF, Caffey EM Jr, Klett CJ (1973) Prophylactic efficacy of lithium carbonate in manicdepressive illness. Arch Gen Psychiatry 28: 334–337Google Scholar
- 16.Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N et al (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64: 1013–1024PubMedCrossRefGoogle Scholar
- 17.Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60: 392–400PubMedCrossRefGoogle Scholar
- 19.Keck PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R; for the Aripiprazole Study Group (2007) Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68: 1480–1491PubMedCrossRefGoogle Scholar
- 20.Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW et al (2005) Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162: 1281–1290PubMedCrossRefGoogle Scholar
- 21.Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL (2006) Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 163: 247–256PubMedCrossRefGoogle Scholar
- 22.Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD et al (2004) Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. Br J Psychiatry 184: 337–345PubMedCrossRefGoogle Scholar
- 23.Bowden CL, Calabrese JR, McElroy SL, Gyulai L,Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ et al (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57: 481–489PubMedCrossRefGoogle Scholar